Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | CTSS | P25774 | 3/20 | 0.46 |
| ▸ | CTSK | P43235 | 3/20 | 0.46 |
| ▸ | PGR | P06401 | 1/20 | 0.42 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | AKT1 | P31749 | 2/20 | 0.41 |
| ▸ | CA12 | O43570 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | CA7 | P43166 | 1/20 | 0.40 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.40 |
| ▸ | NQO2 | P16083 | 1/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6375660 | 1.00 | ALDH1A1 (0.48) | ALDH1A1HSD17B10KDM4EGAAMEN1 | |
| SCHEMBL3004207 | 1.00 | ALDH1A1 (0.48) | ALDH1A1HSD17B10KDM4EGAAMEN1 | |
| SCHEMBL6139046 | 0.88 | ALDH1A1 (0.44) | ALDH1A1HSD17B10KDM4EGAAMEN1 | |
| SCHEMBL7284372 | 0.86 | GAA (0.47) | ALDH1A1HSD17B10KDM4EGAAMEN1 | |
| SCHEMBL28546281 | 0.85 | KDM4E (0.45) | ALDH1A1HSD17B10KDM4EMEN1NPC1 | |
| SCHEMBL1471745 | 0.85 | KDM4E (0.45) | ALDH1A1HSD17B10KDM4EMEN1NPC1 | |
| SCHEMBL27702983 | 0.85 | KDM4E (0.45) | ALDH1A1HSD17B10KDM4EMEN1NPC1 | |
| SCHEMBL7453154 | 0.83 | MEN1 (0.47) | ALDH1A1HSD17B10KDM4EMEN1NPC1 | |
| SCHEMBL2489047 | 0.83 | MEN1 (0.47) | ALDH1A1HSD17B10KDM4EMEN1NPC1 | |
| SCHEMBL3008670 | 0.81 | AKT1 (0.44) | GAAMEN1NPC1RAB9AKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7968548-B2 | Agonist or antgonist and binders and inversion of agonist; use in the treatment of metabolic, immune, infection-related and melanocortin receptor mediated disorders including specifically treatment of obesity and related conditions | PALATIN TECHNOLOGIES, INC. (US) | 2011-06-28 | — | — | US | disclosed |
| CN-101930991-A | Active driving organic electroluminescence device and preparation method thereof | UNIV ELECTRONIC SCIENCE & TECH | 2010-12-29 | — | — | CN | disclosed |
| US-7834017-B2 | Diamine-containing, tetra-substituted piperazine compounds having identical 1- and 4-substituents | PALATIN TECHNOLOGIES, INC. (US) | 2010-11-16 | — | — | US | disclosed |
| US-7727990-B2 | Melanocortin receptor-specific piperazine and keto-piperazine compounds | PALATIN TECHNOLOGIES, INC. (US) | 2010-06-01 | — | — | US | disclosed |
| US-7727991-B2 | Substituted melanocortin receptor-specific single acyl piperazine compounds | PALATIN TECHNOLOGIES, INC. (US) | 2010-06-01 | — | — | US | disclosed |
| US-7405209-B2 | e.g. 2-Benzyloxycarbonylamino-4-methyl-pentanoyl)-3-oxo-azepan-4-ylcarbamoyl}carbamic acid benzyl ester; protease inhibitors like cathepsin K; osteoporosis, osteo- and rheumatoid arthritis and periodontal disease; inhibiting excessive cartilage or matrix degradation | SMITHKLINE BEECHAM CORPORATION (US) | 2008-07-29 | — | — | US | disclosed |
| EP-1922072-A2 | MELANOCORTIN RECEPTOR-SPECIFIC PIPERAZINE COMPOUNDS WITH DIAMINE GROUPS | Palatin Technologies, Inc. (US) | 2008-05-21 | — | — | EP | disclosed |
| EP-1919479-A2 | MELANOCORTIN RECEPTOR-SPECIFIC PIPERAZINE AND KETO-PIPERAZINE COMPOUNDS | Palatin Technologies, Inc. (US) | 2008-05-14 | — | — | EP | disclosed |
| US-20080070921-A1 | Diamine-Containing, Tetra-Substituted Piperazine Compounds Having Identical 1- and 4-Substituents | PALATIN TECHNOLOGIES, INC. (US) | 2008-03-20 | — | — | US | disclosed |
| WO-2008017852-A1 | DIAMINE-CONTAINING, TETRA- SUBSTITUTED PIPERAZINE COMPOUNDS AS MELANOCORTIN RECEPTOR MODULATORS | PALATIN TECHNOLOGIES, INC. (US) | 2008-02-14 | — | — | WO | disclosed |
| US-20030044399-A1 | Method of treatment | SMITHKLINE BEECHAM CORPORATION | 2003-03-06 | — | — | US | disclosed |
| US-20020147188-A1 | Protease inhibitors | SMITHKLINE BEECHAM CORPORATION | 2002-10-10 | — | — | US | disclosed |
| CN-1350458-A | Protease inhibitors | SMITHKLINE BEECHAM CORP (US) | 2002-05-22 | — | — | CN | disclosed |
| EP-1158986-A4 | PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORP (US) | 2002-03-27 | — | — | EP | disclosed |
| WO-2001095911-A1 | PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2001-12-20 | — | — | WO | disclosed |
| EP-1158986-A1 | PROTEASE INHIBITORS | SmithKline Beecham Corporation (US) | 2001-12-05 | — | — | EP | disclosed |
| WO-2000038687-A1 | PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2000-07-06 | — | — | WO | disclosed |
| EP-1001764-A1 | HETEROCYCLIC AMIDE COMPOUNDS AS CELL ADHESION INHIBITORS | Merck & Co., Inc. (a New Jersey corp.) (US) | 2000-05-24 | — | — | EP | disclosed |
| WO-1999064395-A1 | HETEROCYCLIC AMIDE COMPOUNDS AS CELL ADHESION INHIBITORS | MERCK & CO., INC. (US) | 1999-12-16 | — | — | WO | disclosed |
| WO-1998053814-A1 | HETEROCYCLIC AMIDE COMPOUNDS AS CELL ADHESION INHIBITORS | MERCK & CO., INC. (US) | 1998-12-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030044399-A1 | Method of treatment | DNPEP, PEPD, ANPEP | ALDH1A1 1483/4885HSD17B10 1403/4885KDM4E 956/4885 |
| US-20080070921-A1 | Diamine-Containing, Tetra-Substituted Piperazine Compounds Having Identical 1- and 4-Substituents | NPY1R, MC5R, MC4R | ALDH1A1 3437/4885HSD17B10 3194/4885KDM4E 146/4885 |
| US-20020147188-A1 | Protease inhibitors | CTSK, MMP13, CTSZ | ALDH1A1 3651/4885HSD17B10 3057/4885KDM4E 917/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.